InvestorsHub Logo

scottsmith

10/06/16 10:05 AM

#363 RE: Amatuer17 #362

Yea I like their chances to. We got the doctor that's been using this drug for a long time with a great history of success.

tykundegex

10/06/16 4:24 PM

#364 RE: Amatuer17 #362

On the conf call, when asked how an early stop in 2Q2017 would affect timelines to NDA, the CEO said:

"the point here is try to generate efficacy data .. show it to the regulators both in the US and hopefully in Europe, and at the same time in parallel show it to industry. There is obviously a lot of interest from pharma, including big pharma, in this program, and there's [sic] a lot of people who are eager to see meaningful efficacy data which we're trying to generate as quickly as possible for partnering purposes"